Certain medications that are not primarily approved for obesity management but share the same chemical drug under different brand names and labels were separately analyzed in the study to explore potential off-label applications of GLP-1RAs
First 2-4 weeks : During the initial weeks, you experience most side effects as your body is adjusting to the medication
For weight loss purposes specifically, your plan administrator may require a letter of medical necessity from your prescriber
Understanding the typical duration, triggers, and management strategies can help people participating in trials make informed decisions and know when to seek medical advice
Frequencies reflect SmPC classifications: Very common (more than 1 in 10 people): nausea, vomiting, diarrhoea, decreased appetite, particularly during dose escalation Common (up to 1 in 10 people): increased heart rate, injection-site reactions, fatigue, constipation, dyspepsia, abdominal discomfort Uncommon to rare but clinically important: acute pancreatitis, gallbladder disease (including cholelithiasis and cholecystitis) Additional safety considerations per the UK SmPC include: Hypoglycaemia : the risk rises when tirzepatide is used with insulin or a sulfonylurea
